RU93026961A - METHOD FOR OBTAINING INACTIVATED INFLUENZA VACCINE - Google Patents

METHOD FOR OBTAINING INACTIVATED INFLUENZA VACCINE

Info

Publication number
RU93026961A
RU93026961A RU93026961/14A RU93026961A RU93026961A RU 93026961 A RU93026961 A RU 93026961A RU 93026961/14 A RU93026961/14 A RU 93026961/14A RU 93026961 A RU93026961 A RU 93026961A RU 93026961 A RU93026961 A RU 93026961A
Authority
RU
Russia
Prior art keywords
influenza vaccine
inactivated influenza
relates
obtaining inactivated
obtaining
Prior art date
Application number
RU93026961/14A
Other languages
Russian (ru)
Other versions
RU2082431C1 (en
Inventor
Н.И. Чубарова
С.В. Клейменова
И.Ю. Никоноров
Н.Р. Розаева
М.А. Бичурина
Original Assignee
Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им.Пастера
Предприятие по производству бакпрепаратов при НИИЭМ им.Пастера
Filing date
Publication date
Application filed by Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им.Пастера, Предприятие по производству бакпрепаратов при НИИЭМ им.Пастера filed Critical Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им.Пастера
Priority to RU93026961A priority Critical patent/RU2082431C1/en
Priority claimed from RU93026961A external-priority patent/RU2082431C1/en
Publication of RU93026961A publication Critical patent/RU93026961A/en
Application granted granted Critical
Publication of RU2082431C1 publication Critical patent/RU2082431C1/en

Links

Claims (1)

Изобретение относится к медицинской промышленности и касается производства вирусных препаратов, в частности гриппозных вакцин. Сущность изобретения заключается в том, что гельфильтрат вируса обрабатывают трипсином в концентрации 0,5 - 1,0%, который избирательно расщепляет балластные белки (овальбумин и неовальбуминовые антигены), переводя их во фракцию низкомолекулярных соединений. Уровень аллантоисных примесей в вакцинном препарате снижается в 4-16 раз.The invention relates to the medical industry and relates to the production of viral preparations, in particular influenza vaccines. The essence of the invention lies in the fact that the gel filtrate of the virus is treated with trypsin in a concentration of 0.5-1.0%, which selectively cleaves ballast proteins (ovalbumin and neovalbumin antigens), converting them into a fraction of low molecular weight compounds. The level of allantoic impurities in the vaccine preparation is reduced by 4-16 times.
RU93026961A 1993-05-12 1993-05-12 Method of preparing the inactivated antiinfluenza vaccine RU2082431C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU93026961A RU2082431C1 (en) 1993-05-12 1993-05-12 Method of preparing the inactivated antiinfluenza vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93026961A RU2082431C1 (en) 1993-05-12 1993-05-12 Method of preparing the inactivated antiinfluenza vaccine

Publications (2)

Publication Number Publication Date
RU93026961A true RU93026961A (en) 1996-10-20
RU2082431C1 RU2082431C1 (en) 1997-06-27

Family

ID=20141752

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93026961A RU2082431C1 (en) 1993-05-12 1993-05-12 Method of preparing the inactivated antiinfluenza vaccine

Country Status (1)

Country Link
RU (1) RU2082431C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830917B2 (en) * 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof

Similar Documents

Publication Publication Date Title
GEP20084431B (en) Papilloma virus vaccine
NO975434L (en) Process for the preparation of influenza hemagglutinin multivalent vaccines
PT83434B (en) PROCESS OF PREPARATION OF RECOMBINANT, PEPTID, PROTEIN AND VACCINE VIRUSES AGAINST THE ACQUIRED IMMUNODEFICIENCY SYNDROME
DE3588254D1 (en) Gag antigen and its use for the detection of LAV infection, as well as in immunogenic compositions
ATE340859T1 (en) RECOMBINANT PAPILLOMAVIRUS L1 PROTEIN
ATE326479T1 (en) VARIANTS OF HUMAN PAPILLOMA VIRUS ANTIGENS
HUP0102478A2 (en) Particles of hcv envelope proteins: use for vaccination
ES2191663T3 (en) RECOMBINING VIRUS OF THE PORCINE VIRUELA.
ATE97164T1 (en) RECOMBINANT VACCINIA VIRUS MVA.
DK0538437T3 (en) Immunostimulatory and immune boosting, reconstituted influenza viruses and vaccines containing them
DE69519521D1 (en) COMPOSITION CONTAINING AN ANTIQUE-EXPRESSING RECOMBINANT VIRUS AND AN IMMUNE-STIMULATING MOLECULE-EXPRESSING RECOMBINANT VIRUS
BR9500732B1 (en) Diagnostic kit for the detection of antibodies against viruses that cause immunodeficiency.
RU2000116260A (en) LTB ADJUVANT VACCINES
HUP9801334A2 (en) Dna encoding human papilloma virus type 18
DK0480949T3 (en) Preparation of viruses and purification of viral envelope proteins for vaccine use
BR9510520A (en) Papilloma virus capsid protein isolated and purified capsids virus-like particles process of producing the purified protein recombinant papillone virus vaccine pharmaceutical compositions treatment or prevention process against papillary virus infection kit for the detection of papilloma virus or antibodies papillomavirus processes for the production of a recombinant papillone virus capsid protein to induce an immune response in an animalvertebrate synthetic system
SE9903031D0 (en) Peptide mixture and vaccine against a chronic viral infection
EP0252588A3 (en) Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
RU93026961A (en) METHOD FOR OBTAINING INACTIVATED INFLUENZA VACCINE
ATE71534T1 (en) VACCINE.
RU95117445A (en) METHOD FOR OBTAINING A LIVER INFLUENZA VACCINE
WO1998023752A3 (en) Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses
Lachgar et al. Involvement of α-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment
RU2082431C1 (en) Method of preparing the inactivated antiinfluenza vaccine